[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.175.236. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
June 23/30, 1999

Meta-analysis of Tacrine for Alzheimer Disease: The Influence of Industry Sponsors

Author Affiliations
 

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor

JAMA. 1999;281(24):2287-2288. doi:10-1001/pubs.JAMA-ISSN-0098-7484-281-24-jbk0623

To the Editor: The recent favorable meta-analysis of tacrine for treating Alzheimer disease by Dr Qizilbash and colleagues1 did not consider the potential influence of corporate sponsorship on the reported studies. Studies without corporate support found no clinical effect (references 1, 13, 14, 16, and 21 in the article). All but 1 (reference 24) of the manufacturer-supported studies found clinical benefit (references 15, 17-20, and 22). We could not locate 1 study (reference 23).

First Page Preview View Large
First page PDF preview
First page PDF preview
×